DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
O•• L•• T•• O•••• B••••••• I••
Pharmaceuticalsgroup grade Aon a schedule nowsponsor unattributed
Nothing material in the last 200 days. No dated change on record yet.
Mark path, consensus per quarter end
100¢ · 100¢Q1 2025 to Q2 2025
Principal held
at least $40,000
sum of BDC pieces, a lower bound
Fair value
Not disclosed
n/a on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
2
2 on the latest quarter
Facilities
1
1 equity pieces beside them
Next maturity
Jul 11, 2030
no dated debt inside 24 months
On the tape since
Sep 30, 2024
latest Jun 30, 2026
Events
1
dated, non-routine
Lender marks
each lender's own fair value over cost at Jun 30, 2026, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| M••••• F•••••••• I••••••••• C••• | $21K | no cost filed | no comparable mark |
| M••••• A••••• I••••••••• P•••••• L•••••• | $19K | no cost filed | no comparable mark |
Every BDC piece · 4 positions across 2 lenderslargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| M••••• F•••••••• I••••••••• C••• | notes unsecured or subordinated U•••••••• D••• - P••••••••• N••• I••••••• R••• 11.34% M••••••• D••• 07/11/30 | $21,000 | Not disclosed n/a | 11.34% |
| M••••• A••••• I••••••••• P•••••• L•••••• | notes unsecured or subordinated U•••••••• D••• - P••••••••• N••• 11.34% M••••••• D••• 07/11/30 | $19,000 | Not disclosed n/a | 11.34% |
| M••••• A••••• I••••••••• P•••••• L•••••• | equity equity C••••• Equity – S•••• M••••••• D••• 12/31/99 | Not disclosed | Not disclosed n/a | |
| M••••• F•••••••• I••••••••• C••• | equity equity C••••• Equity - C••••• S•••• | Not disclosed | Not disclosed n/a |
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| unsecured or subordinated notes unsecured or subordinated | at least $40,000 | n/a | 11.34% | Jul 11, 2030 | 2 |
Equity pieces beside the debt: equity (Not disclosed fair value, 2 BDCs)
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 2 | $40,000 | $0 | 0c | 0 |
| Mar 31, 2026 | 2 | $40,000 | $0 | 0c | 0 |
| Dec 31, 2025 | 1 | $21,000 | $0 | 0c | 0 |
| Jun 30, 2025 | 1 | $21,000 | $21,000 | 100c | 0 |
All 7 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Mar 31, 2025 | 1 | $21,000 | $21,000 | 100c | 0 |
| Dec 31, 2024 | 1 | $42,000 | $42,000 | 100c | 0 |
| Sep 30, 2024 | 1 | $21,000 | $21,000 | 100c | 0 |
What changed
- New lender joined a facilityMar 31, 2026
- New borrower on a BDC scheduleSep 30, 2024
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- ORA TVG ORION BLOCKERderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 2 BDCsderived
- Industry
- Pharmaceuticalsreportedas one filer wrote it